Osteoprotegerin in primary hyperparathyroidism.
Diabetology and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland.
J
J
Szymczak
Diabetology and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland.
A
A
Bohdanowicz-Pawlak
D019386:Alendronate / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016723:Bone Remodeling; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000628:therapy*; D008297:Male; D053244:Osteoprotegerin / Q000097:blood*; D053245:RANK Ligand / Q000097:blood*
D050071:Bone Density Conservation Agents; D053244:Osteoprotegerin; D053245:RANK Ligand; D019386:Alendronate